Novel Optical Scanning Probe Microscope for Biomedical Chemical Imaging with Ultra-High Spatial Resolution and Chemical Sensitivity
Project Number1R43EB035988-01
Contact PI/Project LeaderUKHANOV, ALEXANDER A Other PIs
Awardee OrganizationACTOPROBE, LLC
Description
Abstract Text
Abstract: Understanding molecular mechanisms of diseases and manipulating them to achieve cure
constitutes one of the "holy Grail" of biomedical science. Infectious (and parasitic) diseases are responsible
for ~30% of premature deaths, especially in low- and middle-income countries. Studies of the pathogenic agents
require high-resolution and high-sensitivity microscopy and spectroscopy equipment, ideally capable of
detecting single molecules of interest (i.e., DNA bases, proteins on viral capsids, etc.). Scanning near-field
optical microscopy (SNOM) combined with near-field nano-spectroscopy- Tip-Enhanced Raman spectroscopy
(TERS) is the best technology for visualization of such nanoscale details. However, the spatial resolution and
chemical sensitivity levels are currently insufficient to detect and identify single molecules in an ambient
environment (air or liquid). Current methods for the identification of infectious agents rely on traditional
methods that include growing of bacteria and fungi, isolation of viruses in cell culture, and then identification of
the agent biochemically, antigenically, or genetically (which require the availability of specific antibodies for
ELISA tests and specific DNA primers for PCR). These methods make the identification of newly emerging
pathogens particularly difficult. New approaches to diagnostics are overdue. Actoprobe LLC proposes such an
approach: to develop, validate, and commercialize a novel class of probes for Scanning Probe Microscopy (SPM)
based on silicon nitride photonics with a diode laser, a pulse compressor, and a detector, all inside the SPM
probe. The ultimate goal is to dramatically (>10X) increase SNOM's sensitivity and spatial resolution for
rapid identification of infectious agents. With its strong research experience and expertise in TERS and SNOM,
Actoprobe is in an ideal position to address this technical challenge. This new TERS tool's capabilities will allow
studying the biochemical components, morphology, and nanomechanical structures of viruses, bacteria,
and fungi at the single-molecule level, substantially improving early infectious disease detection and
identification. We expect the proposed technology will enable substantially improved early pathogenic disease
agent detection and lead to a marketable, cost-effective diagnostic/identification tool. Our primary customers
will be medical laboratories and clinical research institutions. Phase I will prove the technical feasibility of
developing the ultrasensitive optical SPM probes and testing these probes on several non-pathogenic viruses.
Public Health Relevance Statement
Narrative
New infectious disease diagnostic approaches are required to improve diagnostic speed, reliability, and detection
sensitivity, ideally for label-free disease-causing agent detection directly from patient samples. Characterization
of single DNA and RNA at the single-molecule level, however, remains unattainable due to the lack of applicable
technologies that can reach single-molecule resolution and chemical sensitivity. This project will develop a novel
class of scanning probe microscopy near-field optical probes that will provide new and enhanced research
capabilities for studying biochemical components of viruses, bacteria, fungi, and other microorganisms and their
morphology, ultrastructure, and nanomechanical properties, with the ultimate goal to enable very long fragments
of DNA /RNA sequencing with no previous information about the organisms to do early infection detection and
identification.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AddressAirAntibodiesAreaAspergillus fumigatusBacteriaBaculovirusesBiochemicalCOVID-19 outbreakCapsidCell Culture TechniquesCessation of lifeChemicalsClassificationClinicalClinical ResearchCommunicable DiseasesDNADNA PrimersDNA sequencingDedicationsDetectionDiagnosticDiseaseEnvironmentEnzyme-Linked Immunosorbent AssayEquipmentGenus staphylococcusGoalsGrowthHeightImageImaging technologyInfectionInfectious AgentInstitutionLabelLaboratory ResearchLasersLateralLipidsLiquid substanceMarketingMeasurementMeasuresMedicalMembrane ProteinsMethodsMicroscopyMolecularMorphologyNanoscopyNoiseOpticsOrganismOutcomePathogenicityPatientsPhasePhotonsPhysiologic pulsePositioning AttributePreventionPrincipal Component AnalysisPropertyProteinsRNARaman Spectrum AnalysisRapid diagnosticsResearchResolutionSamplingScanningScanning Probe MicroscopesScanning Probe MicroscopyScienceSemiconductorsSignal TransductionSmall Business Innovation Research GrantSpectrum AnalysisSpeedStructureSurfaceTechnologyTestingTimeTobacco Mosaic VirusUnited States National Institutes of HealthVariantViralVirionVirusVisualizationbasecommercializationcostcost effectivedata qualitydesigndetection methoddetection sensitivitydetectordiagnostic strategydisorder controlemerging pathogenexperiencefungushigh volume manufacturingimprovedinnovationinstrumentinterestlow and middle-income countriesmechanical propertiesmicroorganismmolecular diagnosticsnanonanomechanicsnanoscalenear field microscopynovelnovel strategiesoperationphotonicsprematureprototypesilicon nitridesingle moleculesuccesstooltranscriptome sequencingtwo-photonviral detectionvirus identification
National Institute of Biomedical Imaging and Bioengineering
CFDA Code
286
DUNS Number
831840272
UEI
Y81ZJ6567A47
Project Start Date
01-September-2024
Project End Date
31-August-2025
Budget Start Date
01-September-2024
Budget End Date
31-August-2025
Project Funding Information for 2024
Total Funding
$295,308
Direct Costs
$197,135
Indirect Costs
$78,854
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Biomedical Imaging and Bioengineering
$295,308
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R43EB035988-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R43EB035988-01
Patents
No Patents information available for 1R43EB035988-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R43EB035988-01
Clinical Studies
No Clinical Studies information available for 1R43EB035988-01
News and More
Related News Releases
No news release information available for 1R43EB035988-01
History
No Historical information available for 1R43EB035988-01
Similar Projects
No Similar Projects information available for 1R43EB035988-01